e-Therapeutics plc Directors' Dealings and Issue of Equity (8817L)
October 06 2016 - 4:12AM
UK Regulatory
TIDMETX
RNS Number : 8817L
e-Therapeutics plc
06 October 2016
e-Therapeutics plc
('e-Therapeutics' or 'the Company')
Directors' Dealings and Issue of Equity
Oxford and Newcastle, UK, 6 October 2016 - e-Therapeutics plc
(AIM: ETX) the drug discovery company, announces that on 5 October
2016 Professor Trevor Jones (Non-Executive Director) subscribed for
a total of 41,204 new ordinary shares of 0.1p each in the Company
(the "New Ordinary Shares") at an average price of 11.327 pence per
share. The subscription monies paid for the New Ordinary Shares
represent 50% of Professor Jones Non-Executive Director fees net of
tax paid during the period from 1 May 2016 to 30 September
2016.
Application has been made to AIM for the admission of the New
Ordinary Shares to trading on AIM ("Admission") and Admission is
expected to occur on 12 October 2016. The New Ordinary Shares will
rank pari passu in all respects with the Company's existing
ordinary shares in issue.
Following Admission, Professor Jones will be interested in a
total of 70,580 ordinary shares of 0.1p in the Company,
representing approximately 0.03% of the Company's issued share
capital.
Following Admission the total number of ordinary shares in the
Company with voting rights in issue will be 268,389,125. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure and
Transparency Rules.
The Company also announces today that on 5 October 2016
Professor Jones entered into a binding contractual arrangement with
the Company under which he agreed, with effect from 1 October 2016,
to invest 50% of his annual Non-Executive Director fees net of tax
in new e-Therapeutics' ordinary shares.
The new shares will be issued to Professor Jones on the first
business day after 31 December and 30 June in each year. The
subscription price to be paid will be the average of the closing
mid-market price for the five business days prior to the date of
issue. The terms pursuant to which Professor Jones will purchase
the shares are fixed and he has irrevocably committed to such
terms.
1 Details of the person discharging
managerial responsibilities/person
closely associated
---- ------------------------------------------------
a) Name Trevor Jones
---- -------------------- --------------------------
2 Reason for the notification
---- ------------------------------------------------
a) Position/status Director
---- -------------------- --------------------------
b) Initial Initial Notification
notification
/Amendment
---- -------------------- --------------------------
3 Details of the issuer, emission allowance
market participant, auction platform,
auctioneer or auction monitor
---- ------------------------------------------------
a) Name e-Therapeutics plc
---- -------------------- --------------------------
b) Legal Entity N/A
Identifier
---- -------------------- --------------------------
4 Details of the transaction(s): section
to be repeated for (i) each type
of instrument; (ii) each type of
transaction; (iii) each date; and
(iv) each place where transactions
have been conducted
---- ------------------------------------------------
a) Description Ordinary shares of 0.1
of the financial pence each
instrument,
type of
instrument
Identification GB00B2823H99
code
---- -------------------- --------------------------
b) Nature of Purchase of new shares
the transaction
---- -------------------- --------------------------
c) Currency GBP
---- -------------------- --------------------------
d) Price(s) Price(s) Volume(s)
and volume(s)
---- -------------------- -------------- ----------
11.327 pence 41,204
---------------------------------------- ----------
e) Aggregated
information
- Aggregated 41,204
volume
- Price 11.327 pence
- Aggregated GBP4,667.12
total
---- -------------------- --------------------------
f) Date of 5 October 2016
the transaction
---- -------------------- --------------------------
g) Place of London Stock Exchange
the transaction
---- -------------------- --------------------------
-Ends-
Contacts:
e-Therapeutics plc Tel: +44 (0) 1993
Iain Ross, Chairman 883 125
Steve Medlicott, Finance Director www.etherapeutics.co.uk
Numis Securities Limited Tel: +44 (0) 207 260
Michael Meade / Freddie Barnfield 1000
(Corporate Finance) www.numis.com
James Black (Corporate Broking)
Instinctif Partners Tel: +44 (0) 207 457
Melanie Toyne Sewell / Jayne 2020
Crook / Emma Barlow Email: e-therapeutics@instinctif.com
About e-Therapeutics plc
e-Therapeutics (AIM: ETX) is a drug discovery company with a
proprietary discovery platform based on advances in network
pharmacology and chemical biology. The Company is applying its
platform to the discovery of new drug candidates. The therapeutic
focus of the Company's activity is in immuno-oncology, addressing
drug resistance in targeted cancer therapies and anti-infectives.
The platform is highly productive, yielding multiple potent and
selective molecules at a much higher rate and more quickly than is
reported for conventional drug discovery.
e-Therapeutics has a variety of preclinical stage assets,
including ETS2300, telomerase inhibition in anti-cancer; ETS3100,
small molecule anti-TNF<ALPHA>; ETS2400, Hedgehog pathway
inhibition and ETS5200, broad spectrum antivirals. The Company has
recently completed a phase IIb clinical trial for ETS6103, a drug
to treat major depressive disorder.
The Company is fully funded to advance its drug discovery
programmes. It is based in Oxford and Newcastle, UK. For more
information, visit www.etherapeutics.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHMMMGGLVGGVZG
(END) Dow Jones Newswires
October 06, 2016 05:12 ET (09:12 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Mar 2024 to Apr 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2023 to Apr 2024